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Summary/Conclusions: Our global protein expression database for CLL cells
is thus the most complete database of its type. By combining advanced com-
putational biology to relate protein expression to whole genome sequencing
data, the database will provide a framework for elucidating the effect of genomic
alterations on protein expression. The construction of this comprehensive CLL
database also provides the platform for applying SWATH/MS-based analysis
of individual patient samples to identify novel drug targets and predictive bio-
markers of disease progression and treatment response.
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Background: Chronic lymphocytic leukaemia (CLL) is thought to be driven fol-
lowing antigen engagement of the B cell receptor (BCR). This has been high-
lighted further by the BCR Kinase inhibitors Ibrutinib and Idelalisib, which have
proved instrumental in the treatment of CLL. However, these inhibitors appear
to only suppress the disease without being curative. A number of patients have
developed resistance to ibrutinib following mutation of the BTK or PLCγ2 gene,
whilst other patients are unable to tolerate these drugs due to adverse events
or progress whilst on therapy for unknown reasons. B-cell activating factor
(BAFF) and interleukin-4 (IL-4) are known to increase CLL cell viability in vitro,
and are thought to be present within CLL lymph nodes. Therefore we have
investigated the role of BAFF and IL-4 in regulating BCR signalling in CLL cells
and promoting resistance to ibrutinib and idelalisib.
Aims: To understand how IL-4 and BAFF regulate BCR pathway inhibition by
ibrutinib and idelalisib. 
Methods: Experiments were carried out using primary CLL cells. All isolates
used contained >85% CD19+CD5+ cells. Protein expression was evaluated by
flow cytometry or immunoblotting and signalling capacity was detected by cal-
cium flux analysis in response to soluble αIgM by flow cytometry. Cell viability
was assessed using annexin v/propidium iodide staining. 
Results: As previously shown CLL cells treated with BAFF (500 ng/ml) or IL-4
(10 ng/ml) only for 48h significantly protected against basal apoptosis. This
anti-apoptotic effect was further augmented when cells were treated with BAFF
and IL-4 in combination. CLL cells treated in vitro with ibrutinib and idelalisib
induced approximately 24.3% and 28.8% apoptosis respectively following treat-
ment for 48h. However, apoptosis induced by the BCR-kinase inhibitors was
reversed following pre-treatment with IL-4 or BAFF. CLL cells incubated in vitro
with IL-4 for 24h significantly augmented sIgM expression and αIgM induced
phosphorylated ERK and calcium flux. These IL-4 induced effects on sIgM
expression were more prominent in Unmutated(U)-CLL samples, and could be
reversed using the JAK3 inhibitor tofacitinib (CP-690550). Whilst, IL-4 had little
effect on sIgD. Interestingly pre-treating CLL cells with IL-4 significantly reversed
the ability of ibrutinib (1 µM) and idelalisib (1 µM) to inhibit αIgM-mediated sig-
nalling at 24h. In contrast BAFF treatment showed no clear effect on sIgM
expression and downstream signalling. However, in a proportion of CLL sam-
ples treated simultaneously with BAFF and IL-4, BAFF reduced IL-4 specific
increases in sIgM augmentation. Next we pre-treated CLL cells with tofacitinib
(10 µM) for 1 hr prior to IL-4 treatment. Tofacitinib significantly reversed the
effects observed with IL-4 and restored the ability of ibrutinib and idelalisib to
inhibit αIgM induced signalling. This effect was specific to the inhibition of IL-4
since tofacitinib (≤10 µM) did not induce CLL cell death. Finally we showed
that BAFF, and IL-4 to a greater extent, resulted in an increase in miRNA155
expression which has previously been shown to be associated with more pro-
gressive disease and enhanced BCR signalling.
Summary/Conclusions: Our data suggests that IL-4 augments sIgM recovery
and down-stream signalling in CLL, which may compromise the effectiveness
of BCR kinase inhibitors. However these effects were not observed for BAFF.
Furthermore, co-treatment of BCR-kinase inhibitors in combination with tofac-
itinib may indicate a promising treatment strategy for the treatment of CLL.
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Background: Standard immune-chemotherapy allows to achieve 60-70%
response rate in CLL patients, but complete remission remains uncommon.
Unsatisfactory therapeutic options still exist for higher risk groups, and in par-
ticular those harboring TP53 mutations or deletion.
Aims: We propose USP7, a known de-ubiquitinase with multiple roles in cellular
homeostasis, as a potential therapeutic target in CLL.
Methods: Primary CLL cells were enriched in CD19+ fraction using the Milteny
anti-CD19 kit and were used to investigate USP7 levels. P5091 (USP7 inhibitor)
efficacy was tested in CLL cell lines and patients. Proliferation and apoptosis
were evaluated respectively with CTG technology and Annexin V-FITC/Propid-
ium PE detection by flow cytometry. The specificity of the USP7 inhibitor was
verified with a pool of 5 different siRNAs able to efficiently silence USP7.
Results: Our data show that the de-ubiquitinase USP7 is aberrantly expressed
in CLL. In particular, USP7 is over-expressed in about 70% of CLL CD19+ lym-
phocytes, both at the mRNA and protein levels. We also analyzed USP7 expres-
sion levels in an expansion cohort of a publicly available CLL patients (n=217)
and 12 normal samples, where USP7 was over-expressed in CLL when com-
pared to normal samples (****p<0.0001). We proved that USP7 is regulated at
post-transcriptional level by miR-338-3p and functionally activated by Casein
Kinase 2 (CK2) through phosphorylation at serine 18 residue. USP7 inhibition by
P5091 as well as by specific siRNA, induces cell growth arrest and apoptosis
mediated by the restoration of the nuclear pool of PTEN. Notably in primary CLL
cells, P5091 treatment strongly promoted apoptosis. Moreover, USP7 inhibitor
treatment of primary CLL was associated with increases ubiquitination of endoge-
nous PTEN and consequently PTEN relocalization into the nucleus. Strikingly,
TP53 deleted CLL samples and cells lines were equally subject to P5091 apop-
tosis induction, confirming that the USP7 inhibitor acts in a p53 independent man-
ner. These data showed potent activity of P5091 against primary CLL.
Summary/Conclusions: We demonstrate the efficacy of a small molecule
inhibitor of USP7, P5091, in vitro in cell lines and ex vivo in primary CLL samples
in a P53-independent manner. Our preclinical study therefore, supports the
evaluation of USP7 inhibitor as a potential CLL therapy.
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Background: Resistance against chemotherapy is a central problem in the
current treatment of B cell malignancies. Up until now, little is known about the
impact of the tumor microenvironment on therapeutic outcome. This microen-
vironment consists of many different kinds of cells varying between tumors,
significantly manipulating malignancy and enabling relapses after treatment.
Macrophages are present in the microenvironment of most tumors-designated
as tumor associated macrophages (TAM)-and are often correlated to a poor
prognosis. We postulate that macrophages and their reprogramming are an
essential element in the malignant progression of tumors and their response to
DNA damage as occurring in chemotherapeutic treatment and are a promising
target to improve therapy response.
Aims: We aim to define the functional characteristics of macrophages in their
cross talk with malignant B cells and characterize their role for disease pro-
gression and antitumor therapy. Our particular interest lies on the investigation
of the functional mechanistic and kinetics underlying macrophage repolarisa-
tion. Here, we intend to identify key regulators and their upstream signaling
pathways by focusing on the DNA damage pathway.
Methods: To assess macrophage leukemia cell interaction we established in
vitro and ex vivo co-cultures of macrophages and leukemic cells, specifically
investigating macrophage antibody dependent cellular phagocytic (ADCP)
capacities. Leukemic cell clearance and macrophage phenotype characteriza-
tion are determined by flow cytometry. We addressed both primary CLL patient
cells as well as humanized mouse model of BCL2/MYC double hit lymphoma.
Results: Functionally we prove that low dose application of the in vitro equivalent
of Cyclophosphamide, Mafosfamide significantly increases the phagocytic func-
tion of macrophages. Besides this direct effect on macrophages, a combination
of cyclophosphamide and alemtuzumab was demonstrated to induce a
macrophage based increase in tumor clearance by cytokine secretion of stressed
malignant B cells. Here, we could determine IL10 as an inducer of increased
phagocytosis in tumor associated macrophages. Moreover we show that IL10
modulates differentiation of macrophages which strongly increases their ADCP
compared to classical M1/M2 differentiated macrophages. Analyzing the func-
tional contribution of the DNA-damage pathway we could identify pronounced
secretion of IL10 in p53-deficient leukemia cells. We show in vitro that the DNA
damage pathway plays an important role in the ASAP mechanism as a down
regulation of various DNA damage key players in the leukemic cells diminishes
the stimulating effect of Cyclophosphamide and antibody combinations.
Summary/Conclusions: Repolarisation of macrophages towards increased
phagocytosis is essential in immunochemotherapies. We demonstrate that the
DNA damage pathway is important for this stimulating effect and that the mech-
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